Suraksha Diagnostic reported a significant improvement in profitability for the quarter ended June 30, 2026, with standalone net profit rising 27.6% year-on-year to ₹125.8 lakh. The growth was underpinned by a 19.6% increase in revenue from operations to ₹840.8 lakh, outpacing the 19.2% rise in total expenses.

Consolidated figures showed even stronger momentum, with net profit attributable to owners of the parent climbing 38.6% to ₹130.0 lakh, compared to ₹93.9 lakh in Q1FY25. Consolidated revenue from operations expanded 20.7% to ₹876.4 lakh. The company’s earnings per share (basic) increased to ₹2.42 on a standalone basis and ₹2.50 on a consolidated basis, up from ₹1.89 and ₹1.80 respectively in the prior year period.

Financial Performance

The financial results reflect improved operational efficiency alongside top-line growth. While employee benefits expenses rose 11.6% to ₹138.5 lakh (standalone), other expenses grew at a faster pace of 17.6% to ₹308.4 lakh. However, the revenue growth trajectory was steeper than the cost inflation, leading to an expansion in pre-tax profit margins.

What the Numbers Show

A key observation from the filing is the divergence between standalone and consolidated performance drivers. While standalone profit grew 27.6%, consolidated profit attributed to parent owners surged 38.6%. This suggests that subsidiaries contributed disproportionately to the bottom-line improvement in this quarter, despite the holding company bearing a larger share of administrative or corporate overheads reflected in the standalone "other expenses" line item, which stood at ₹308.4 lakh versus ₹262.2 lakh in Q1FY25.

Additionally, finance costs decreased slightly in the standalone entity by 5.0% to ₹36.7 lakh, indicating potential optimization in debt servicing or interest rates, which positively impacted the pre-tax margin expansion.

Corporate Actions

During its meeting on August 12, 2026, the Board of Directors approved several key administrative decisions:

• CFO Appointment: Mr. Dinesh Gupta has been appointed as Chief Financial Officer, effective August 24, 2026. He will also serve as Group CFO. Gupta brings over 14 years of experience, including tenures at Saranyu Power Trading, Genpact, and Maersk Global Services.
• Dividend Record Date: Tuesday, September 15, 2026, has been fixed as the record date for determining shareholder entitlement to the FY25 dividend. Payment will be made within the statutory period following approval at the AGM.
• AGM Notice: The revised notice for the 21st Annual General Meeting has been approved. The meeting is scheduled for Tuesday, September 22, 2026, via video conferencing/other audio-visual means (VC/OAVM).

Legal Disclosures

The company disclosed an ongoing dispute with the Government of Meghalaya involving a step-down subsidiary. As of June 30, 2026, the recoverability of investments, loans, and trade receivables aggregating to ₹393.6 lakh is under assessment. Management has provided a provision of ₹81.1 lakh on these balances on a prudent basis. Arbitration proceedings are sub judice, with the next hearing scheduled for August 21, 2026, at the High Court of Meghalaya.

Suraksha Diagnostic Limited has postponed its 21st Annual General Meeting (AGM), originally scheduled for Wednesday, September 02, 2026. The company notified the stock exchanges on August 10, 2026, stating that the meeting stands postponed to a future date due to certain unavoidable circumstances. This development impacts shareholders who were preparing to vote on agenda items at the upcoming assembly.

The intimation was issued pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It serves as a continuation of an earlier intimation letter dated May 21, 2026. The company emphasized that the revised date, time, and venue for the 21st AGM will be decided in accordance with the Companies Act, 2013, read with rules made thereunder, and the SEBI LODR Regulations, 2015. Once finalized, these details will be formally informed to the Stock Exchanges and shareholders.

Key Details of the Postponement

The communication was signed by Ritu Mittal, Joint Managing Director & CEO of Suraksha Diagnostic Limited. The company expressed regret for any inconvenience caused to shareholders on account of the postponement. No specific new date was provided in this filing; instead, the company committed to informing stakeholders when the schedule is finalized.

This procedural update ensures compliance with regulatory disclosure norms while managing shareholder expectations regarding the timing of the annual assembly. Investors are advised to monitor official communications from the company and the stock exchanges for further updates on the rescheduled AGM date.